Udhayvir Grewal(@UGrewalMD):Authors’ conclusion: The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC (which is misleading). Correct conclusion: Atezolizumab led to inferior outcomes compared to FFX/bev plus atezo despite the well-established superiority of ICI over cytotoxic chemotherapy in MSI-H colorectal cancer, calling into question its role as the ICI of choice in this population. Should this make you worried about ATOMIC? The answer should be 100% My go-to for adjuvant therapy in MSI-H colon cancer is off-label PD-1 or on our clinical trial of toripalimab monotherapy led by my colleague Dr Emiloju @WinshipAtEmory

2026.07.30 21:53

Authors’ conclusion: The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC (which is misleading). Correct conclusion: Atezolizumab led to inferior outcomes compared to FFX/bev plus atezo despite the well-established superiority of ICI over cytotoxic chemotherapy in MSI-H colorectal cancer, calling into question its role as the ICI of choice in this population. Should this make you worried about ATOMIC? The answer should be 100% My go-to for adjuvant therapy in MSI-H colon cancer is off-label PD-1 or on our clinical trial of toripalimab monotherapy led by my colleague Dr Emiloju @WinshipAtEmory